tiprankstipranks
Trending News
More News >
Medmira Inc (TSE:MIR)
:MIR

Medmira (MIR) AI Stock Analysis

Compare
38 Followers

Top Page

TS

Medmira

(MIR)

Rating:50Neutral
Price Target:
C$0.00
▼(-100.00%Downside)
Medmira's overall stock score is primarily impacted by its significant financial challenges, including negative margins and dependency on external funding. While technical indicators and valuation reflect some risks, recent corporate events provide a positive outlook with strategic product developments and partnerships. Investors should weigh these factors carefully, considering both the financial risks and potential growth opportunities.

Medmira (MIR) vs. iShares MSCI Canada ETF (EWC)

Medmira Business Overview & Revenue Model

Company DescriptionMedmira Inc. is a biotechnology company that operates in the healthcare sector, specializing in the development and manufacturing of rapid diagnostic solutions. The company is headquartered in Halifax, Canada, and is known for its expertise in creating point-of-care testing products. Medmira’s core offerings include diagnostic tests for infectious diseases such as HIV, Hepatitis, and Syphilis, leveraging its patented Rapid Vertical Flow (RVF) Technology.
How the Company Makes MoneyMedmira makes money through the sale of its rapid diagnostic test kits to healthcare providers, clinics, and distributors worldwide. The company's revenue model is primarily based on product sales, with its rapid tests being the key revenue streams. Medmira collaborates with various distribution partners to expand its market reach and accessibility of its products. Additionally, the company seeks to enhance its earnings through strategic partnerships and licensing agreements that allow it to leverage its proprietary technology in new markets or applications.

Medmira Financial Statement Overview

Summary
Medmira is facing severe financial challenges. The income statement indicates negative growth and profitability, with high financial leverage and negative equity on the balance sheet, raising solvency concerns. Cash flow inefficiencies further exacerbate operational difficulties. Overall, significant improvements are required for financial health.
Income Statement
20
Very Negative
Medmira's income statement reveals significant challenges. The company is experiencing declining revenue growth with a negative gross profit margin, indicating cost inefficiencies in production. Net profit margin is negative, suggesting sustained losses, and both EBIT and EBITDA margins are negative, highlighting operational difficulties.
Balance Sheet
15
Very Negative
The balance sheet shows high financial leverage with a negative stockholders' equity, indicating potential solvency issues. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative, reflecting financial instability. These factors suggest a high-risk financial position.
Cash Flow
25
Negative
Cash flow analysis shows negative free cash flow, indicating the company is not generating sufficient cash to cover capital expenditures. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting revenue into cash. However, the cash flow from financing activities is positive, indicating dependency on external funding to support operations.
BreakdownTTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income Statement
Total Revenue276.73K412.57K432.53K952.13K2.14M919.07K
Gross Profit-8.96K226.49K-434.91K304.03K1.72M572.28K
EBITDA-3.13M-2.13M-1.58M-1.07M185.30K-1.13M
Net Income-4.46M-3.33M-2.68M-1.83M-675.80K-2.05M
Balance Sheet
Total Assets4.20M6.07M3.65M3.83M3.89M3.40M
Cash, Cash Equivalents and Short-Term Investments295.62K2.10M13.18K33.46K-2.30M401.86K
Total Debt9.49M9.56M9.27M8.30M11.54M11.91M
Total Liabilities24.74M24.11M18.68M16.19M19.61M18.96M
Stockholders Equity-20.54M-18.04M-15.03M-12.36M-15.72M-15.56M
Cash Flow
Free Cash Flow-4.17M-3.68M-1.27M-1.95M-541.19K-417.78K
Operating Cash Flow-3.42M-2.94M-1.27M-1.88M-504.64K-315.90K
Investing Cash Flow-746.19K-742.53K-1.27K-69.72K-36.55K-101.88K
Financing Cash Flow3.61M5.77M1.25M1.99M139.32K730.74K

Medmira Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.08
Price Trends
50DMA
0.08
Negative
100DMA
0.09
Negative
200DMA
0.09
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
43.45
Neutral
STOCH
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MIR, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.45 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MIR.

Medmira Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
TSCOV
74
Outperform
C$65.80M17.0614.51%28.97%
TSMBX
66
Neutral
C$41.47M25.435.32%-4.67%-60.94%
TSMIR
50
Neutral
C$59.15M
-33.66%-48.89%
49
Neutral
AU$2.48B4.18-64.25%2.84%36.51%13.13%
TSONC
43
Neutral
$92.38M-211.24%0.10%
TSSVA
33
Underperform
C$54.20M248.46%32.71%
TSHBP
33
Underperform
C$68.96M685.26%-50.29%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:MIR
Medmira
0.08
0.00
0.00%
TSE:ONC
Oncolytics Biotech
1.04
-0.37
-26.24%
TSE:HBP
Helix BioPharma
0.93
-0.25
-21.19%
TSE:COV
Covalon Technologies
2.40
0.30
14.29%
TSE:SVA
Sernova
0.16
-0.18
-52.94%
TSE:MBX
Microbix Biosystms
0.30
0.00
0.00%

Medmira Corporate Events

Product-Related AnnouncementsFinancial DisclosuresRegulatory Filings and Compliance
MedMira Reports Q2 FY2025 Results, Advances in STI and HIV Testing
Positive
Jul 1, 2025

MedMira Inc. reported its second quarter financial results for FY2025, highlighting significant advancements in product launches and regulatory progress. The company introduced its Health Canada approved Multiplo® TP/HIV and Reveal® Rapid HIV Test in Canada, generating strong demand and working towards expanding its STI product portfolio. MedMira is also pursuing regulatory approvals in the U.S. for its Reveal® G4 HIV-1/2 rapid test and is in discussions to accelerate the commercialization of its MiROQ technology. Despite increased operating expenses due to clinical trials, these developments position MedMira for enhanced market access and potential growth.

Product-Related AnnouncementsBusiness Operations and Strategy
MedMira Partners with Lovell to Enhance Federal Access to Rapid HIV Testing
Positive
Apr 17, 2025

MedMira Inc. has partnered with Lovell Government Services to expand access to its Reveal® G4 HIV-1/2 rapid test within federal healthcare systems, including the Veterans Health Administration and the Military Health System. This collaboration allows MedMira to leverage Lovell’s status as a Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor, facilitating the procurement of their products through various federal contracting systems. The partnership is expected to enhance MedMira’s market reach and streamline the acquisition process for government agencies, thereby supporting federal procurement goals and improving healthcare delivery for veterans.

Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
MedMira Achieves Regulatory Milestones Amidst Financial Challenges in Q2 FY2025
Neutral
Apr 2, 2025

MedMira Inc. reported its Q2 FY2025 financial results, highlighting significant regulatory achievements, including Health Canada approval for its Multiplo® Rapid TP/HIV Test and Reveal® Rapid HIV Test. The company expanded its market reach through new distribution agreements in Canada and the USA. Despite recording a net loss and increased operating expenses due to clinical trials, MedMira anticipates revenue growth driven by the demand for its testing solutions. The company is also pursuing regulatory clearance for home testing applications, which could further enhance its market position.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 01, 2025